



PRIOR AUTHORIZATION REQUEST

EMFLAZA

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for ALL PA requests. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

1 Is the request for an INITIAL or a CONTINUATION of therapy?

Initial (If checked, go to 7)

Continuation (If checked, go to 2)

2 Is the patient currently receiving the requested medication? Yes No

[If no, skip to question 7.]

**If you have any
questions, call:
1-888-258-8250**

Version 04.2026

PRIOR AUTHORIZATION REQUEST

3	Has the patient been receiving medication samples of the requested medication? [If yes, skip to question 7.]	Yes	No
4	Does the patient have a previously approved prior authorization (PA) on file with the current plan? [Note: If the patient does NOT have a previously approved PA on file for the requested medication with the current plan, the renewal request will be considered under initial therapy.] [If no, skip to question 7.]	Yes	No
5	Has the patient been established on therapy for AT LEAST 3 months? [If no, skip to question 7.]	Yes	No
6	Has documentation been submitted to confirm that the patient has had a significant response to therapy, as determined by the provider? ACTION REQUIRED: Submit supporting documentation. [No further questions.]	Yes	No
7	What is the diagnosis or indication? <input type="checkbox"/> Duchenne Muscular Dystrophy (DMD) (If checked, go to 8) <input type="checkbox"/> Other (If checked, no further questions)		
8	What is the requested medication? <input type="checkbox"/> Deflazacort (generic) (If checked, go to 10) <input type="checkbox"/> Emflaza (brand) (If checked, go to 9)		
9	Has the patient had a trial and failure of the generic product, deflazacort? [If no, no further questions.]	Yes	No
10	Is the patient greater than or equal to 2 years of age? [If no, no further questions.]	Yes	No
11	Has documentation been provided to confirm that the patient has tried prednisone for GREATER THAN or EQUAL to 6 months? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 14.]	Yes	No
12	Has documentation been provided to confirm that, according to the prescriber, the patient has had a significant intolerable adverse effect (that is Cushingoid appearance, central [truncal] obesity, undesirable weight gain defined as a GREATER THAN or EQUAL TO 10% of body weight gain increase over a 6-month period, diabetes and/or hypertension that is difficult to manage according to the prescriber)? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 14.]	Yes	No

**If you have any
questions, call:
1-888-258-8250**

Version 04.2026



PRIOR AUTHORIZATION REQUEST

13	Has documentation been provided to confirm that, according to the prescriber, the patient has experienced a severe behavioral adverse effect while on prednisone therapy that has or would require a prednisone dose reduction? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
14	Is the requested medication being prescribed by or in consultation with a physician who specializes in the treatment of Duchenne Muscular Dystrophy (DMD) and/or neuromuscular disorders? [If no, no further questions.]	Yes	No
15	Does the requested dose exceed the Food and Drug Administration (FDA) approved label dosing for the requested indication? [Dosing: 0.9 mg/kg once daily.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

**If you have any
questions, call:
1-888-258-8250**

Version 04.2026